<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225963</url>
  </required_header>
  <id_info>
    <org_study_id>CE15180B</org_study_id>
    <nct_id>NCT03225963</nct_id>
  </id_info>
  <brief_title>Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.</brief_title>
  <official_title>Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab has become the standard of care of recurrent glioblastoma based on promising
      clinical trial results with with response rates up to 50% and progression-free survival up to
      9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab
      response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there
      are some angiogenesis biomarker available for prediction of bevacizumab response later.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response of bevacizumab therapy.</measure>
    <time_frame>3 months after bevacizumab therapy</time_frame>
    <description>Base on the image after bevacizumab therapy (after recurrence)</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Angiogenesis</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiation with temozolomide</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA of peripheral mononulcear cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obtain peripheral blood pre-chemotherapy, mid-chemoradition and post-chemoraidtion
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 20 year old.

          -  Glioblastoma patients who will receive chemoradiation treatment.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weir Chiang You, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Institutional Review Board of Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weir Chiang You, M.D. Ph.D.</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>5602</phone_ext>
    <email>bigjohnyou@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Lin Yeh, M.D.</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>5621</phone_ext>
    <email>yehl@vghtc.gov.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weir Chiang You, M.D. PhD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>5602</phone_ext>
      <email>bigjohnyou@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res. 2003 Apr;9(4):1399-405.</citation>
    <PMID>12684411</PMID>
  </reference>
  <reference>
    <citation>Reynés G, Vila V, Martín M, Parada A, Fleitas T, Reganon E, Martínez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011 Mar;102(1):35-41. doi: 10.1007/s11060-010-0290-x. Epub 2010 Jul 6.</citation>
    <PMID>20607353</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

